HomeAboutRankingsData Sources
© 2026 GeneE
🧬
GeneE
10 sources retrieved · Most recent: April 2026 · Index updated 14 days ago
ⓘGeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
MYO10
myosin X
Chromosome 5 · 5p15.1
NCBI Gene: 4651Ensembl: ENSG00000145555.15HGNC: HGNC:7593UniProt: B7Z3D4
96PubMed Papers
20Diseases
0Drugs
1Pathogenic Variants
FUNCTIONAL ROLE
Transporter
DATA QUALITY
✓ Experimental GO Evidence✓ Swiss-Prot Reviewed
spectrin bindingregulation of cell shapeprotein bindingcytosolalcohol drinkingeye diseaseParalytic ileusCOVID-19
✦AI Summary

MYO10 (myosin X) is an unconventional actin-based motor protein with multifaceted roles in cellular morphodynamics and disease pathology. Its primary function involves promoting filopodia formation and elongation through its motor domain and multifunctional tail domain 1, with the tail domain being particularly crucial for sustaining long filopodial structures. Beyond filopodia, MYO10 facilitates cytoskeleton-dependent intracellular transport and can mediate mitochondrial transfer between cells via tunneling nanotube formation 2. Mechanistically, MYO10 acts as a plus-end directed microfilament motor that binds actin filaments and phosphatidylinositol-3,4,5-trisphosphate, enabling cellular protrusion dynamics and intracellular cargo transport. In neuroprotection, satellite glial cell-derived MYO10 facilitates mitochondrial transfer to sensory neurons, with reduced MYO10 expression in diabetic conditions correlating with impaired transfer and neuropathic pain 2. Clinically, MYO10 exhibits stage-dependent roles in cancer progression. In early-stage breast cancer (DCIS), MYO10-dependent filopodia support basement membrane integrity and limit invasion 3. Conversely, in advanced malignancies including melanoma, squamous cell lung cancer, and colorectal cancer, elevated MYO10 expression promotes metastasis, cell migration, and invasion 4567. MYO10 expression serves as a prognostic biomarker for overall survival in lung cancer and predicts chemotherapy response 6.

Sources cited
1
MYO10 is expressed in satellite glial cells and facilitates mitochondrial transfer to sensory neurons via tunneling nanotube formation; reduced MYO10 expression in diabetes impairs mitochondrial transfer and contributes to peripheral neuropathy
PMID: 41501451
2
MYO10 tail domain is crucial for promoting long filopodia; filopodia elongate through multiple elongation cycles supported by the MYO10 tail
PMID: 38043799
3
MYO10 promotes filopodia formation and is elevated in DCIS and invasive breast cancer; MYO10-filopodia support basement membrane integrity at pre-invasive tumor boundaries
PMID: 36283390
4
MYO10 is known for filopodia formation and is implicated in cancer metastasis and pathogen infection; MYO10 knockdown limits cancer cell motility and pathogen spread
PMID: 25819274
5
MYO10 is overexpressed in melanoma tissues and positively correlated with malignant phenotypes and unfavorable prognosis; MYO10 silencing inhibits melanoma cell proliferation, migration, invasion, and tumor growth
PMID: 40050821
6
MYO10 is upregulated by TGFβ stimulation in squamous cell lung cancer; MYO10 expression ratio predicts overall survival and chemotherapy response in lung cancer patients
PMID: 29934580
7
MYO10 functions in the COX-2-MYO10 signaling axis to promote filopodia generation and metastasis in colorectal cancer; COX-2 inhibitors interfere with this axis to suppress cancer cell migration and invasion
PMID: 37749237
Disease Associationsⓘ20
alcohol drinkingOpen Targets
0.37Weak
eye diseaseOpen Targets
0.35Weak
Paralytic ileusOpen Targets
0.34Weak
COVID-19Open Targets
0.33Weak
connective tissue diseaseOpen Targets
0.33Weak
placenta praeviaOpen Targets
0.31Weak
Abnormality of the integumentOpen Targets
0.30Weak
VertigoOpen Targets
0.29Weak
psoriatic arthritisOpen Targets
0.29Weak
thyroiditisOpen Targets
0.29Weak
Parkinson diseaseOpen Targets
0.27Weak
pneumococcal pneumoniaOpen Targets
0.27Weak
musculoskeletal system diseaseOpen Targets
0.27Weak
HypercholesterolemiaOpen Targets
0.21Weak
Peyronie diseaseOpen Targets
0.21Weak
retinopathyOpen Targets
0.20Weak
external ear diseaseOpen Targets
0.19Weak
retinoschisisOpen Targets
0.18Weak
Benign Thyroid Gland NeoplasmOpen Targets
0.18Weak
coronary artery diseaseOpen Targets
0.13Weak
Pathogenic Variants1
NM_012334.3(MYO10):c.841_844del (p.Ser281fs)Likely pathogenic
not provided
★☆☆☆2024→ Residue 281
View on ClinVar ↗
Related Genes
CALML3Protein interaction100%DCCProtein interaction99%CALM1Protein interaction99%CALM2Protein interaction99%ACTG1Protein interaction97%ACTBProtein interaction96%
Tissue Expression6 tissues
Brain
100%
Lung
82%
Ovary
67%
Heart
31%
Liver
29%
Bone Marrow
14%
Gene Interaction Network
Click a node to explore
MYO10CALML3DCCCALM1CALM2ACTG1ACTB
PROTEIN STRUCTURE
Preparing viewer…
PDB5I0H · 1.80 Å · X-ray
View on RCSB ↗
Constraintⓘ
LOEUFⓘ
0.63LoF Tolerant
pLIⓘ
0.00Tolerant
Observed/Expected LoF0.54 [0.47–0.63]
RankingsWhere MYO10 stands among ~20K protein-coding genes
  • #4,992of 20,598
    Most Researched96 · top quartile
  • #4,902of 5,498
    Most Pathogenic Variants1
  • #4,436of 17,882
    Most Constrained (LOEUF)0.63 · top quartile
Genes detectedMYO10
Sources retrieved10 papers
Response time—
📄 Sources
10▼
1
Mitochondrial transfer from glia to neurons protects against peripheral neuropathy.
PMID: 41501451
Nature · 2026
1.00
2
Myosin-X and disease.
PMID: 25819274
Exp Cell Res · 2015
0.90
3
Unveiling ac4C modification pattern: a prospective target for improving the response to immunotherapeutic strategies in melanoma.
PMID: 40050821
J Transl Med · 2025
0.80
4
Production and Functional Verification of 8-Gene (GGTA1, CMAH, β4GalNT2, hCD46, hCD55, hCD59, hTBM, hCD39)-Edited Donor Pigs for Xenotransplantation.
PMID: 40190036
Cell Prolif · 2025
0.70
5
Rosmarinic acid in combination with ginsenoside Rg1 suppresses colon cancer metastasis via co-inhition of COX-2 and PD1/PD-L1 signaling axis.
PMID: 37749237
Acta Pharmacol Sin · 2024
0.60